CCCC
C4 Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.76
+0.45%0
Insider buys (3m)
0
Insider sells (3m)
$0.00
Net value (3m)
-3.0%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Jul 13, 2026 | REYNO LEONARD · officer: Chief Medical Officer | M-Exempt | 15,325 | $0.00 |
| Jul 13, 2026 | REYNO LEONARD · officer: Chief Medical Officer | F-InKind | 7,397 | $4.06 |
| Jul 2, 2026 | GROGAN DONNA ROY · director | A-Award | 3,341 | $4.34 |
| Jul 2, 2026 | Anderson Kenneth Carl · director | A-Award | 2,650 | $4.34 |
| Jun 26, 2026 | Hoerter Steven L. · director | A-Award | 62,000 | $4.25 |
| Jun 26, 2026 | Bessen Laura · director | A-Award | 62,000 | $4.25 |
| Jun 26, 2026 | Cooper Ronald Harold Wilfred · director | A-Award | 62,000 | $4.25 |
| Jun 26, 2026 | Fawell Stephen · director | A-Award | 62,000 | $4.25 |
| Jun 26, 2026 | Koppikar Utpal · director | A-Award | 62,000 | $4.25 |
| Jun 26, 2026 | Hughes Owen · director | A-Award | 62,000 | $4.25 |
| Jun 26, 2026 | GROGAN DONNA ROY · director | A-Award | 62,000 | $4.25 |
| Jun 26, 2026 | Anderson Kenneth Carl · director | A-Award | 62,000 | $4.25 |
| Jun 4, 2026 | Anderson Kenneth Carl · director | M-Exempt | 1,070 | $2.11 |
| Apr 3, 2026 | GROGAN DONNA ROY · director | A-Award | 5,370 | $2.70 |
| Apr 3, 2026 | Anderson Kenneth Carl · director | A-Award | 4,259 | $2.70 |
| Feb 18, 2026 | Hirsch Andrew · director, officer: President & CEO | M-Exempt | 81,725 | $0.00 |
| Feb 18, 2026 | Boyle Scott N · officer: Chief Business Officer | A-Award | 200,000 | $0.00 |
| Feb 18, 2026 | Mossler Mark · officer: Chief Accounting Officer | M-Exempt | 9,420 | $0.00 |
| Feb 18, 2026 | Adams Kendra · officer: Chief Financial Officer | F-InKind | 15,381 | $1.89 |
| Feb 18, 2026 | Schick Kelly · officer: Chief People Officer | M-Exempt | 20,950 | $0.00 |
| Feb 18, 2026 | Mahaney Paige · officer: Chief Scientific Officer | A-Award | 240,000 | $0.00 |
| Feb 18, 2026 | Adams Kendra · officer: Chief Financial Officer | F-InKind | 1,863 | $1.89 |
| Feb 18, 2026 | Adams Kendra · officer: Chief Financial Officer | M-Exempt | 3,750 | $0.00 |
| Feb 18, 2026 | Adams Kendra · officer: Chief Financial Officer | M-Exempt | 30,950 | $0.00 |
| Feb 18, 2026 | Schick Kelly · officer: Chief People Officer | F-InKind | 7,269 | $1.89 |
| Feb 18, 2026 | Mahaney Paige · officer: Chief Scientific Officer | M-Exempt | 7,050 | $0.00 |
| Feb 18, 2026 | Hirsch Andrew · director, officer: President & CEO | A-Award | 700,000 | $0.00 |
| Feb 18, 2026 | Mossler Mark · officer: Chief Accounting Officer | F-InKind | 3,268 | $1.89 |
| Feb 18, 2026 | Boyle Scott N · officer: Chief Business Officer | F-InKind | 1,735 | $1.89 |
| Feb 18, 2026 | Hirsch Andrew · director, officer: President & CEO | F-InKind | 9,057 | $1.89 |
Institutional positioning
13F filings over the trailing two quarters
New 86Increased 95Reduced 62Sold out 27
| Filer | Action | Shares | Filed |
|---|---|---|---|
| MORGAN STANLEY | Reduced | 9,072,400 | May 15, 2026 |
| MORGAN STANLEY | Reduced | 8,867,338 | Aug 13, 2026 |
| RA CAPITAL MANAGEMENT, L.P. | Unchanged | 8,000,000 | May 15, 2026 |
| RA CAPITAL MANAGEMENT, L.P. | Unchanged | 8,000,000 | Aug 14, 2026 |
| BlackRock, Inc. | Increased | 7,896,718 | Aug 7, 2026 |
| Squadron Capital Management LLC | Increased | 7,600,000 | Aug 14, 2026 |
| Lynx1 Capital Management LP | Increased | 7,326,691 | Aug 13, 2026 |
| BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC | Unchanged | 7,171,910 | May 15, 2026 |
| Bain Capital Life Sciences Investors, LLC | Unchanged | 7,171,910 | Aug 14, 2026 |
| LYNX1 CAPITAL MANAGEMENT LP | Reduced | 6,998,902 | May 4, 2026 |
| JPMORGAN CHASE & CO | Increased | 4,747,424 | Aug 12, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | Increased | 4,417,731 | Aug 13, 2026 |
| CITADEL ADVISORS LLC | Increased | 4,284,280 | Sep 2, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | New Position | 3,861,852 | May 15, 2026 |
| SOLEUS CAPITAL MANAGEMENT, L.P. | Unchanged | 3,803,942 | May 14, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Jul 13, 2026